Cipla Ltd

Ticker: CIPLA
Decent 68/100

☆ Add to Watchlist
Rebound

Investing Reference

Price
1501.30
Market Cap
121270.69
Debt/Equity
0.0140
ROE %
18.152
PB
3.8758
Promoter %
29.214
Pledge %
0.000
1Y Rev Growth %
7.122
5Y Rev Growth %
10.206
NP Margin %
18.559
NP Margin 5Y Avg %
13.992

Trading Reference

1M Return %
2.339
6M Return %
-1.593
1Y Return %
-3.251
% Away 52W High
11.437
% Away 52W Low
12.457
Daily Volume
3365093
Investment Verdict
Hold
Score 65/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 30/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.

Summary

Cipla Ltd shows strong growth potential driven by robust product pipeline and expanding global presence.

✅ Positives
  • Strong revenue growth in key therapeutic areas
  • Expanding presence in international markets
  • Robust R&D pipeline with new launches

⚠️ Negatives
  • Regulatory challenges in certain markets
  • Intense competition affecting pricing power
  • Currency fluctuations impacting profitability

Verdict
Cipla Ltd is well-positioned for growth.
Recommendation: Consider buying for long-term gains.
Upside Probability: 25%   |   Downside Probability: 15%
Last generated: 30/10/2025

More Options

Business Overview

Cipla Ltd is a leading Indian pharmaceutical company dedicated to providing high-quality medicines and healthcare solutions. With a strong focus on innovation and accessibility, Cipla caters to a diverse range of therapeutic areas including respiratory, cardiovascular, and oncology. The company plays a crucial role in improving health outcomes for millions, making essential treatments affordable and available. Cipla's commitment to research and development ensures it remains at the forefront of the industry, positively impacting lives across India and beyond.

  • Established leader in the pharmaceutical sector
  • Wide range of therapeutic solutions
  • Focus on affordability and accessibility
  • Strong commitment to research and innovation
  • Positive impact on public health
  • Global presence with local expertise

Investment Thesis

Cipla Ltd stands out as a strong investment choice due to its credible promoter group, robust growth in digital services, and attractive valuation compared to peers. With a solid foundation and strategic initiatives, Cipla is well-positioned for long-term growth in the pharmaceutical sector.

  • Strong promoter credibility enhances investor confidence.
  • Significant growth potential in digital health services.
  • Attractive valuation metrics compared to industry peers.
  • Consistent financial performance and dividend history.
  • Strategic focus on innovation and market expansion.

Opportunity vs Risk

Opportunities
  • Strong pipeline of new drugs
  • Growing demand for generic medicines
  • Expansion into international markets
  • Strategic partnerships with healthcare firms
Risks ⚠️
  • Regulatory challenges in drug approvals
  • Intense competition in generics
  • Currency fluctuations affecting profits
  • Rising raw material costs

Peer Perspective

Cipla Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, reflecting concerns over margin stability. A sustained improvement in operational efficiency could trigger a rerating in its valuation.

Future Outlook

Cipla Ltd is well-positioned for growth, driven by strong product pipelines and expanding markets; however, successful execution and cost control will be crucial to fully capitalize on these opportunities.

AI FAQs for Retail Users

  • Q: What does Cipla Ltd do?
    A: Cipla Ltd is a pharmaceutical company that develops and manufactures a wide range of medicines.
  • Q: Is Cipla a good investment?
    A: Investment suitability depends on individual financial goals and market conditions; consider consulting a financial advisor.
  • Q: What are the main products of Cipla?
    A: Cipla produces generic and branded medications, including respiratory, cardiovascular, and anti-infective drugs.
  • Q: How is Cipla's performance in the market?
    A: Cipla's market performance varies; check recent financial reports and market analysis for updates.
  • Q: What are the risks of investing in Cipla?
    A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
📊 Stock Investment Checklist (100 Points)
Cipla Ltd • Updated: 2025-09-17 06:28:42
  • 10
    Business
    High
    Cipla operates in the pharmaceutical sector, which is essential and has growth potential due to increasing healthcare needs.
  • 10
    Growth
    High
    The company has shown consistent revenue and profit growth over the past few years.
  • 10
    Profitability
    High
    Cipla maintains a healthy ROE and ROCE, with operating cash flow supporting net profits.
  • 8
    Valuation
    High
    Valuation metrics like P/E and P/B are in line with industry averages, suggesting fair valuation.
  • 7
    Balance
    High
    The balance sheet shows manageable debt levels and adequate liquidity.
  • 6
    Governance
    Good
    Promoter holding is stable, but there are concerns about pledging.
  • 5
    Drivers
    Good
    Growth drivers include new product launches, but execution risks remain.
  • 5
    Technicals
    Good
    Market sentiment is mixed, with some volatility in price action.
Final Score & Verdict
Score 68 / 100 • Decent
Cipla Ltd shows a decent investment profile with consistent growth and profitability, though some risks and governance concerns exist.

AI Confidence Score

Instead of just “overall score,” broken into categories:

  • Business Strength: 75/100
  • Growth Potential: 70/100
  • Profitability: 68/100
  • Governance: 80/100
  • Market Confidence: 72/100


More Like This

Latest News

More ↗

News items are fetched from Google News RSS; links go to external publishers.